The Arthritis Foundation thanks the governors in eight states for signing biosimilar legislation in 2018 that enhances patient access to new and innovative medications, while ensuring that pharmacists are communicating critical, up-to-date medical information about patients to physicians. New laws in Connecticut, Michigan, New Hampshire, South Dakota, Vermont, Wyoming, West Virginia and Wisconsin will positively impact approximately 5.3 million people with doctor-diagnosed arthritis.
“This legislation will grant access to life-changing medications while ensuring proper safeguards for both patient and physician when a prescription is substituted,” said Connecticut Advocacy Chair Paula Haney.
Continue reading Biosimilar Substitution Victories Across the Country!
With new, innovative arthritis medications coming to market, patients with arthritis may soon have access to potentially less expensive biosimilar medications (similar to biologics).
However, imagine that, without your knowledge, your pharmacy substituted the biologic medication prescribed by your doctor with a new interchangeable biosimilar. Residents of Arizona no longer have to worry because this week, Arizona Governor Doug Ducey signed House Bill 2310 (HB 2310) into law. HB 2310 allows pharmacists to substitute biologic medications with new, interchangeable and potentially less expensive biosimilar medications when they come to market. The bill also ensures patients and their physicians know when a substitution occurs, resulting in a complete and accurate patient medical record. And, if physicians do not want a substitution to occur, they can stipulate that the prescription be dispensed as written.
Continue reading Arizona Arthritis Advocates Achieve Biosimilar Substitution Victory!